SCHEMBL3150754

SCHEMBL3150754

CC1(C)CC(=O)Nc2cc(NC(=O)c3cccnc3NCc3ccnc(OCC(F)(F)F)c3)ccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.58
KIT P10721 2/20 0.58
BRAF P15056 2/20 0.58
CIT O14578 1/20 0.58
MAP3K7 O43318 1/20 0.58
RIPK2 O43353 1/20 0.58
STK10 O94804 1/20 0.58
MAP4K4 O95819 1/20 0.58
ABL1 P00519 1/20 0.58
EGFR P00533 1/20 0.58
RAF1 P04049 1/20 0.58
LCK P06239 1/20 0.58
FYN P06241 1/20 0.58
CSF1R P07333 1/20 0.58
YES1 P07947 1/20 0.58
LYN P07948 1/20 0.58
RET P07949 1/20 0.58
HCK P08631 1/20 0.58
PDGFRB P09619 1/20 0.58
FGR P09769 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3141507 0.90 KDR (0.62) KDRKITBRAFCITMAP3K7
SCHEMBL3150757 0.85 KDR (0.64) KDRKITBRAFCITMAP3K7
SCHEMBL3155311 0.85 KDR (0.64) KDRKITBRAFCITMAP3K7
SCHEMBL3159833 0.85 KDR (0.79) KDRKITBRAFCITMAP3K7
SCHEMBL3154257 0.84 KDR (0.56) KDRKITBRAFCITMAP3K7
SCHEMBL6105956 0.84 KDR (0.66) KDRKITBRAFCITMAP3K7
SCHEMBL3155435 0.81 KDR (0.59) KDRKITBRAFCITMAP3K7
SCHEMBL447085 0.80 KDR (0.78) KDRKITBRAFCITMAP3K7
SCHEMBL3151947 0.79 KDR (0.67) KDRKITBRAFCITMAP3K7
SCHEMBL3151279 0.79 KDR (0.47) KDRKITBRAFCITMAP3K7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050261313-A1 Substituted alkylamine derivatives and methods of use AMGEN INC. 2005-11-24 US claimed
US-6878714-B2 Substituted alkylamine derivatives and methods of use AMGEN INC. (US) 2005-04-12 US claimed
US-20030225106-A1 Substituted alkylamine derivatives and methods of use AMGEN INC. 2003-12-04 US claimed
US-7687643-B2 Process for preparing 3,3-dimethylindolines AMGEN INC. (US) 2010-03-30 US disclosed
US-7687643-B2 Process for preparing 3,3-dimethylindolines AMGEN INC. (US) 2010-03-30 US disclosed
US-7687643-B2 Process for preparing 3,3-dimethylindolines AMGEN INC. (US) 2010-03-30 US disclosed
US-20050261313-A1 Substituted alkylamine derivatives and methods of use AMGEN INC. 2005-11-24 US disclosed
US-6878714-B2 Substituted alkylamine derivatives and methods of use AMGEN INC. (US) 2005-04-12 US disclosed
US-20030225106-A1 Substituted alkylamine derivatives and methods of use AMGEN INC. 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225106-A1 Substituted alkylamine derivatives and methods of use NAT1, PIGO, AADAC KDR 15/4885KIT 829/4885BRAF 867/4885
US-20050261313-A1 Substituted alkylamine derivatives and methods of use NAT1, PIGO, AADAC KDR 15/4885KIT 829/4885BRAF 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.